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OBJECTIVES: Previous studies have demonstrated the role of inflammation in acute heart failure. The
neutrophil-to-lymphocyte ratio was found to be a useful inflammatory marker for predicting adverse
outcomes. We hypothesized that an elevated neutrophil-to-lymphocyte ratio would be associated with
increased mortality in acute heart failure patients.
METHODS: The study cohort consisted of 167 acute heart failure patients with an ejection fraction ,50%. The
primary endpoint was in-hospital mortality, and the patients were divided into two groups according to in-
hospital mortality.
RESULTS: In a multivariate regression analysis, including baseline demographic, clinical, and biochemical
covariates, the neutrophil to lymphocyte ratio remained an independent predictor of mortality (OR 1.156, 95%
CI 1.001 - 1.334, p=0.048).
CONCLUSION: In conclusion, an elevated neutrophil-to-lymphocyte ratio seems to be a predictor of short-term
mortality in patients with acute heart failure and a reduced left ventricular ejection fraction.
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& INTRODUCTION
Acute heart failure (AHF) is the term used to describe the
rapid onset of or change in symptoms and signs of heart
failure (HF) (1). The prevalence of the syndrome is
increasing due to the frequency of coronary artery disease
and the growing elderly population. In addition, AHF is
associated with high mortality and morbidity (2). Therefore,
the early identification of patients at high risk of AHF is
important. Many prognostic factors have been found to be
related to AHF in past studies (3-10). Several of these factors
are associated with inflammation. Additionally, there have
been studies of inflammation in AHF patients (11-13).
The neutrophil-to-lymphocyte ratio (NLR) in the periph-
eral blood is reported to be an easily assessable factor. An
increased neutrophil count might reflect inflammation, and
lymphopenia is an indicator of physiologic stress. Data on
the ability of the NLR to predict cardiovascular risk in
different patient groups have been reported(14-19).
However, the relationship between the NLR and in-hospital
mortality in AHF patients has not been assessed. We
hypothesized that an elevated NLR would be associated
with increased mortality in AHF patients.
& METHODS
From January 2010 through October 2012, consecutive
patients who were hospitalized at our center because of
AHF were recruited. Included patients were required to
have the following: progressive dyspnea associated with
clinical signs of pulmonary congestion that required
hospitalization and a left ventricular ejection fraction
(LVEF) ,50%. Patients with known evidence of acute
myocardial ischemia, cardiogenic shock, hematological
disease, neoplastic metastases to the bone marrow, sepsis,
pregnancy, severe arthritis, inflammatory bowel diseases,
infection, chronic inflammatory conditions, glucocorticoid
therapy, a history of glucocorticoid use 3 months before
admission, and/or other extracellular fluid-increasing dis-
eases (e.g., hypothyroidism and liver cirrhosis) were
excluded. Patient baseline characteristics and in-hospital
data were recorded on case report forms. All patients
underwent LVEF assessment before or ,24 hours after
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admission. Patients who were admitted from the ER mostly
underwent an echocardiogram in the ER before admission.
Patients who were admitted from the clinic underwent an
echocardiogram in the intensive care unit or ward after
admission. The hospital’s institutional review board
approved the study.
All venous blood samples were obtained upon patient
presentation, before administration of drugs. Total white
blood cell, neutrophil, and lymphocyte counts were
obtained on admission using an automated blood cell
counter. The NLR was calculated as the ratio of the
neutrophil count to the lymphocyte count, both obtained
from the same automated blood sample on admission of the
study population.
All analyses were performed using SPSS V 15.0 for
Windows (SPSS, Chicago, IL). The baseline characteristics of
the groups were compared using analysis of variance for
continuous variables and the x2 statistic for categorical
variables. Logistic regression analyses were performed to
assess the respective independent effects of several variables
on mortality. Odds ratios (ORs) and corresponding 95%
confidence intervals (CIs) are reported for each covariate.
For all tests, which were two-sided, a p-value,0.05 was
considered to indicate a statistically significant difference.
& RESULTS
A total of 167 consecutive patients were admitted to our
institution with AHF during the study duration. Table 1
presents the baseline clinical characteristics according to in-
hospital mortality. Group 1 consisted of patients who died
in the hospital. Group 1 comprised more elderly indivi-
duals, and patients in this group more frequently under-
went monitoring for atrial fibrillation (AF) on admission. In
addition, this group had lower ejection fraction (EF) values
compared with those of the other group. Other parameters
were similar between the two groups. Figure 1 shows that
in an ROC curve analysis, the NLR value needed to detect
in-hospital mortality with a sensitivity of 66.7% and a
specificity of 60.5% was 4.78. The area under the curve was
0.687.
As shown in Table 2, we performed univariate logistic
regression including NLR values and other risk factors for
mortality. Table 3 presents the factors associated with
mortality that were analyzed in the multivariate logistic
regression model. Age, EF, and the NLR (OR 1.156, 95% CI
1.001 - 1.334, p= 0.048) were found to be independent
predictors of in-hospital mortality.
Table 1 - Baseline characteristics of the patients.
Group 1 Group 2 p-value
N 15 152
Age 75¡8 67¡9 0.002
Male (%) 40 62.5 0.079
Ischemic HF (%) 52.3 61.8 0.352
Hypertension (%) 60 57.1 0.531
Diabetes mellitus (%) 53.3 50.7 0.529
Hyperlipidemia (%) 60 36.2 0.065
History of percutaneous intervention (%) 46.7 37.5 0.333
History of coronary artery bypass grafting (%) 20 14.5 0.396
Atrial fibrillation (%) 60 28.9 0.017
NYHA class III or IV 80 73.7 0.428
Use of beta-blockers (%) 33.3 40.1 0.413
Use of ACEI (%) 73.3 65.6 0.384
Use of spironolactone (%) 26.3 33.6 0.411
Use of diuretics (%) 40 39.5 0.587
Ejection fraction (%) 30¡6 34¡7 0.025
Serum hemoglobin levels (g/dl) 12.5¡1.7 12.2¡1.8 0.585
Serum Na levels (mmol/l) 132¡4 134¡5 0.141
Serum creatinine levels (mg/dl) 1.4¡0.8 1.2¡0.5 0.161
Mean NLR 7.2¡4.8 4.8¡3 0.007
NYHA: New York Heart Association.
HF: Heart failure.
ACEI: Angiotensin-converting enzyme inhibitor.
NLR: Neutrophil-to-lymphocyte ratio.
Figure 1 - ROC curve for NLR values.
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& DISCUSSION
The main finding in this study was that high NLR values
were strong predictors of the in-hospital mortality of
patients with AHF, independent of other cardiovascular
risk factors. To our knowledge, this is the first study to
examine this relationship.
AHF is a very dynamic clinical entity, and its risk is
greatest during the first few hours. Therefore, early risk
stratification is very important. In this way, early-identified
high-risk patients are directed toward more intensive and
advanced treatment options. Thus, mortality and morbidity
may be reduced.
There are many studies on the association of AHF and
inflammation (11,20). Markers of inflammation can provide
information about the prognosis of AHF. Lymphocyte and
neutrophil counts are markers and may vary depending on
the severity of inflammation. Lymphopenia is a common
finding during stress responses due to increased levels of
corticosteroids and lymphocyte apoptosis (21).
The lymphocyte count is reduced in patients with
different cardiovascular disturbances. Bian and colleagues
found that a low percentage of lymphocytes could be used
as an independent predictor of acute coronary syndrome on
admission (22). Studies have shown that a decreased
relative percentage of lymphocytes is associated with
morbidity and mortality in AHF patients (23,24). In
addition, similar studies reported an association with an
increased number of neutrophils. Cooper and colleagues
reported that the baseline white blood cell count is an
independent predictor of mortality in patients with LV
dysfunction (25). Both an elevated neutrophil count and a
reduced lymphocyte count may be associated with a poor
cardiovascular prognosis. Thus, the NLR can be used as a
prognostic marker.
There are many studies on the use of the NLR in
cardiovascular disease (14,15,17,26). Nu´n˜ez et al. found that
the NLR was a useful marker for predicting subsequent
mortality in patients admitted for myocardial infarction
with ST-segment elevation (18). Another study found that
the NLR is related to no reflow and in-hospital adverse
events (14). A similar study on AHF was performed.
Uthamalingam and colleagues reported that a higher NLR
is associated with an increased risk of long-term mortality
in patients admitted with AHF (27). The results of our study
are similar. However, we evaluated in-hospital mortality in
our study. In addition, the average EF value was lower in
our study.
In contrast to other studies, certain parameters known to
be associated with mortality (e.g., Na levels, functional
status, atrial fibrillation) were not related to prognosis in our
study. Similar to other studies, age and EF were related to
mortality (7,28,29). However, the mortality rate was slightly
higher in our study. The reason for this finding was likely
the low rate of using optimal medical therapy (especially
beta-blockers). One other reason may be that only patients
with systolic heart failure were included in our study.
Our study has certain limitations. First, other inflamma-
tory markers were not analyzed and compared with the
NLR. In addition, focusing on cardiac mortality and not
including rehospitalizations in the study endpoints could be
considered a limitation of this study. Finally, this study
represents a small number of patients. Although the blood
sampling at presentation was performed before drug
administration in all patients, the time of fasting was
variable among the patients, which might have had a
potential influence on the results. Therefore, a larger
prospective study should be performed to emphasize the
clinical importance and application of measurements of the
NLR in AHF.
In conclusion, an elevated NLR seems to be a predictor of
short-term mortality in patients with AHF and a reduced
LVEF. The NLR is an easily derived and routinely available
measure. Therefore, it might assist in identifying patients at
increased risk of mortality.
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